Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1974 Jun;51(2):237–247. doi: 10.1111/j.1476-5381.1974.tb09653.x

The relation between the adrenergic neurone-blocking and noradrenaline-depleting actions of some guanidine derivatives

ET Abbs, MG Dodd
PMCID: PMC1776754  PMID: 4451743

Abstract

1 The effects of some guanidine derivatives, (—)-N-(1-phenylethyl) guanidine (PEG), guanethidine and debrisoquine have been investigated on the content and subcellular distribution of noradrenaline in cat spleen and on the overflow of noradrenaline from this organ during stimulation of the splenic nerve.

2 PEG and guanethidine, at a dose of 5 mg/kg, produced adrenergic neurone blockade within 15 min and the same dose of debrisoquine produced blockade within 30 minutes.

3 All three compounds produced a decrease of similar magnitude in the noradrenaline content of the high-speed particulate (P2) and supernatant (S) fractions of splenic homogenates; these actions were temporally correlated with the adrenergic neurone-blocking action of the compounds.

4 PEG did not produce any further decrease in the noradrenaline content of the subcellular fractions at times up to 18 h after its administration; adrenergic neurone blockade was maintained throughout this period but had disappeared after 7 days when the noradrenaline content of the subcellular fractions was restored to control levels.

5 Guanethidine, in contrast, caused a marked progressive loss of the transmitter from all subcellular fractions-an effect which was maximal 18 h after its administration but continued, as did the adrenergic neurone-blocking action, for at least 72 hours. This additional loss of noradrenaline, over and above that seen after 15 min, is unlikely to be connected with the adrenergic neurone-blocking action of the drug.

6 Dexamphetamine both prevented and antagonized the neurone blockade and the subcellular noradrenaline-depleting action of PEG and guanethidine. The restoration of nerve function after administration of dexamphetamine to animals pretreated with 5 mg/kg of either of these compounds was temporally correlated with a selective repletion of the noradrenaline content of the supernatant fraction of the spleen.

7 Larger doses (15 mg/kg) of PEG or guanethidine produced a selective depletion of noradrenaline in only the supernatant fraction of the spleen. This depletion was temporally correlated with the adrenergic neurone-blocking action of these compounds. The lack of effect of the compounds at this dose level on the noradrenaline contained in the P2 fraction may be due to `stabilization' of the store of noradrenaline in vivo which gives rise to this fraction on homogenization.

8 It is suggested that the guanidine-type adrenergic neurone-blocking agents displace the noradrenaline which is readily available for release by nerve impulses, and that it is this action that may account for their sympathomimetic properties.

9 The ability of these guanidines to impair the release of noradrenaline by nerve impulses could occur because whilst they are present within the neurone the `nerve-releasable store', which may in these experiments appear in the supernatant fraction after homogenization, may be unable to refill with transmitter.

Full text

PDF
237

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbs E. T., Pycock C. J. The effects of bretylium on the subcellular distribution of noradrenaline and on adrenergic nerve function in rat heart. Br J Pharmacol. 1973 Sep;49(1):11–22. doi: 10.1111/j.1476-5381.1973.tb08263.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Abbs E. T., Robertson M. I. Selective depletion of noradrenaline: a proposed mechanism of the adrenergic neurone-blocking action of bretylium. Br J Pharmacol. 1970 Apr;38(4):776–791. doi: 10.1111/j.1476-5381.1970.tb09887.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Abbs E. T. The release of catechol amines by choline 2,6-XYLYL ether, bretylium and guanethidine. Br J Pharmacol Chemother. 1966 Jan;26(1):162–171. doi: 10.1111/j.1476-5381.1966.tb01818.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. BOURA A. L., COPP F. C., DUNCOMBE W. G., GREEN A. F., McCOUBREY A. The selective accumulation of bretylium in sympathetic ganglia and their postganglionic nerves. Br J Pharmacol Chemother. 1960 Jun;15:265–270. doi: 10.1111/j.1476-5381.1960.tb01242.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. BURN J. H. A new view of adrenergic nerve fibres, explaining the action of reserpine, bretylium, and guanethidine. Br Med J. 1961 Jun 10;1(5240):1623–1627. doi: 10.1136/bmj.1.5240.1623. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. CAMPOS H. A., STITZEL R. E., SHIDEMAN F. E. ACTIONS OF TYRAMINE AND COCAINE ON CATECHOLAMINE LEVELS IN SUBCELLULAR FRACTIONS OF THE ISOLATED CAT HEART. J Pharmacol Exp Ther. 1963 Sep;141:290–300. [PubMed] [Google Scholar]
  7. CASS R., KUNTZMAN R., BRODIE B. B. Norepinephrine depletion as a possible mechanism of action of guanethidine (SU 5864), a new hypotensive agent. Proc Soc Exp Biol Med. 1960 Apr;103:871–872. doi: 10.3181/00379727-103-25702. [DOI] [PubMed] [Google Scholar]
  8. CASS R., SPRIGGS T. L. Tissue amine levels and sympathetic blockade after guanethidine and bretylium. Br J Pharmacol Chemother. 1961 Dec;17:442–450. doi: 10.1111/j.1476-5381.1961.tb01131.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Carlsson A. Modification of sympathetic function. Pharmacological depletion of catecholamine stores. Pharmacol Rev. 1966 Mar;18(1):541–549. [PubMed] [Google Scholar]
  10. Dearnaley D. P., Geffen L. B. Effect of nerve stimulation on the noradrenaline content of the spleen. Proc R Soc Lond B Biol Sci. 1966 Dec 13;166(1004):303–315. doi: 10.1098/rspb.1966.0101. [DOI] [PubMed] [Google Scholar]
  11. FIELDEN R., GREEN A. L., WILEY G. L. ADRENERGIC NEURONE BLOCKING ACTIVITY OF SOME ARALKYLGUANIDINES. Br J Pharmacol Chemother. 1965 Apr;24:395–407. doi: 10.1111/j.1476-5381.1965.tb01727.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. GAFFNEY T. E., CHIDSEY C. A., BRAUNWALD E. Study of the relationship between the neurotransmitter store and adrenergic nerve block induced by reserpine and guanethidine. Circ Res. 1963 Mar;12:264–268. doi: 10.1161/01.res.12.3.264. [DOI] [PubMed] [Google Scholar]
  13. HARRISON D. C., CHIDSEY C. A., GOLDMAN R., BRAUNWALD E. Relationships between the release and tissue depletion of norepinephrine from the heart by guanethidine and reserpine. Circ Res. 1963 Mar;12:256–263. doi: 10.1161/01.res.12.3.256. [DOI] [PubMed] [Google Scholar]
  14. Robertson M. I., Abbs E. T. Catecholamine depletion and adrenergic neurone blockade: studies with debrisoquine. J Neurochem. 1971 Oct;18(10):1999–2001. doi: 10.1111/j.1471-4159.1971.tb09605.x. [DOI] [PubMed] [Google Scholar]
  15. SCHANKER L. S., MORRISON A. S. PHYSIOLOGICAL DISPOSITION OF GUANETHIDINE IN THE RAT AND ITS UPTAKE BY HEART SLICES. Int J Neuropharmacol. 1965 Feb;4:27–39. doi: 10.1016/0028-3908(65)90044-4. [DOI] [PubMed] [Google Scholar]
  16. Spriggs T. L. Peripheral noradrenaline and adrenergic transmission in the rat. Br J Pharmacol Chemother. 1966 Jan;26(1):271–281. doi: 10.1111/j.1476-5381.1966.tb01830.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES